SEARCHNARRATIVE_REVIEWneurology, preclinical research

narrative_review·neurology, preclinical research, biomedical research·PMC10528775

Research progress of the CXCR4 mechanism in Alzheimer's disease

Ibrain · 4 authors, 4 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This narrative review summarizes preclinical research on the CXCR4/CXCL12 signaling axis, which is implicated in inflammatory responses in Alzheimer's disease pathology through microglia and astrocytes. It proposes this axis as a potential therapeutic target, though its specific role in disease development requires further study.

Full summary

328 CHARS

They discuss the potential for targeting microglia and astrocytes as a therapeutic approach. The review concludes that the specific role of CXCR4 in AD, how the axis regulates downstream molecules, and its interactions with other pathways remain unclear and require further elucidation to provide a basis for clinical treatment.

STUDY TYPE

narrative_review

SPECIALTY

neurology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10528775

Research progress of the CXCR4 mechanism in Alzheimer's disease

Ibrain

READ THE FULL PAPER

ABSTRACT

Abstract Alzheimer's disease (AD) is a degenerative brain disease with complex clinical manifestations and pathogeneses such as abnormal deposition of beta‐amyloid protein and inflammation caused by the excessive activation of microglia. CXC motif chemokine receptor type 4 (CXCR4) is a type of G protein‐coupled receptor that binds to CXC motif ligand 12 (CXCL12) to activate downstream signaling pathways, such as the Janus kinase/signal transducer and activator of transcription and the renin–angiotensin system (Ras)/RAF proto‐oncogene serine (Raf)/mitogen‐activated protein kinase/extracellular‐regulated protein kinase; most of these signaling pathways are involved in inflammatory responses. CXCR4 is highly expressed in the microglia and astrocytes; this might be one of the important causes of inflammation caused by microglia and astrocytes. In this review, we summarize the mechanism and therapeutics of AD, the structures of CXCR4 and the CXCL12 ligand, and the mechanisms of CXCR4/CXCL12 that are involved in the occurrence and development of AD. The possible treatment of AD through microglia and astrocytes is also discussed, with the aim of providing a new method for the treatment of AD.

CITATION EXPORT

Qiu‐Lin Wang, Chang‐Le Fang, Xue‐Yan Huang et al.. Research progress of the CXCR4 mechanism in Alzheimer's disease. Ibrain. (2022). https://doi.org/10.1002/ibra.12026

AUTHORS

4 · 4 CENTRES

Qiu‐Lin Wang, Chang‐Le Fang, Xue‐Yan Huang, Lu‐Lu Xue

1 Department of Clinical Medicine Chongqing Medical University Chongqing China
2 Department of Anesthesiology Southwest Medical University Luzhou Sichuan China
3 Department of Anesthesiology The Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China
4 State Key Laboratory of Biotherapy of Sichuan University Chengdu Sichuan China